医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Physio-Control to Acquire HeartSine®

2015年09月15日 AM01:01
このエントリーをはてなブックマークに追加


 

REDMOND, Wash.

Physio-Control has reached an agreement with HeartSine Technologies to acquire the Northern Ireland-based automated external defibrillator (AED) manufacturer, the companies announced today. The two privately held companies recently completed due diligence. Financial details of the transaction are not being released. The combination creates one of the world’s largest AED solutions providers.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150914005333/en/

“With Physio-Control and HeartSine now united in our lifesaving missions, we will be able to offer a tremendous range of AED solutions to our global customers and partners,” said Physio-Control CEO Brian Webster. “Sudden cardiac arrest is one of the biggest health care problems in the world and AEDs are a critical part of the solution. The global market for these devices is growing fast and our joint aim is to save more lives with more AEDs in more places.”

The companies share a strong scientific and technical focus with important, often parallel histories. The pioneer of direct current defibrillation, Physio-Control has partnered with leading emergency medical systems since the 1960s and commercialized the first home use AED, the LIFEPAK 100, in 1986. HeartSine’s founder, Professor John Anderson, worked with the pioneer of out-of-hospital mobile coronary care, Dr. Frank Pantridge, in Belfast in the 1960s and 1970s. Professor Anderson was part of the team that developed the world’s first mobile coronary care unit.

“This is very good for HeartSine and our distributors. Our teams share a strong clinical focus, and together we have exciting opportunities ahead for technical, scientific and marketing collaboration,” said HeartSine CEO Declan O’Mahoney. “Most importantly, we have a strong cultural fit and a common mission to prevent unnecessary deaths from sudden cardiac arrest.”

HeartSine’s products include the samaritan® PAD line of public access AEDs, and technologies such as CPR Advisor™, that provides real-time CPR feedback. Physio-Control’s AED products include the LIFEPAK® CR Plus and LIFEPAK 1000, distributed in 104 countries.

LIFEPAK AEDs are designed and manufactured at the company’s Redmond, Washington, headquarters facility and HeartSine products are designed and manufactured in Belfast, Northern Ireland.

About Physio-Control:
Physio-Control, Inc. is headquartered in Redmond, Washington. The company was founded in 1955 and is the world’s leading provider of professional emergency medical response solutions that predict or intervene in life-threatening emergencies. The company’s products include LIFEPAK® monitor/defibrillators and automated external defibrillators, the LIFENET® System, HealthEMS® electronic patient care reporting (ePCR) software, LUCAS® 2 Chest Compression System, TrueCPR coaching device, McGrath® MAC EMS video laryngoscope and implementation for PulsePoint mobile bystander response applications. Learn more at www.physio-control.com, or connect via www.facebook.com/physiocontrolinc, https://www.linkedin.com/company/physio-control-inc- Twitter: @PhysioControl

About HeartSine Technologies:
HeartSine Technologies, a world leader in personal and public access defibrillators, advances the deployment of lifesaving defibrillation therapy for the treatment of sudden cardiac arrest in non-traditional areas of care. Designed for use in public areas, the company’s entire line of AED products leverages its proprietary, clinically advanced SCOPE™ technology to optimize the administration of lifesaving treatment. The company’s products include the samaritan® PAD family of AEDs for public access. HeartSine is active in over 70 countries worldwide in a wide range of environments. HeartSine is based in Belfast, Northern Ireland and Newtown, Pennsylvania. To learn how a HeartSine AED can save lives, please visit www.heartsine.com or follow HeartSine on Facebook and Twitter.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150914005333/en/

CONTACT

Physio-Control (USA)
Matt Fikse, +1 425-867-4208
matt.fikse@physio-control.com
or
HeartSine
(USA)
René Williams, +1 949-395-3383
rene.williams@heartsine.com

同じカテゴリーの記事 

  • MRMヘルス、回腸嚢炎治療薬MH002の第2a相臨床試験で安全性と良好な有効性データを報告
  • KBIバイオファーマ、Jean-Baptiste Agnus氏を最高業務責任者(CBO)に指名
  • 佐賀大学とBostonGeneがEGFR陽性肺癌患者におけるICIの治療効果予測因子を特定するための新規バイオマーカー探索を目的とした研究を発表
  • KBI Biopharma任命Jean-Baptiste Agnus为首席商务官
  • First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome